FOLH1 and prostate carcinoma: 335 men with biopsy‐proven prostate carcinoma and imaging using prostate‐specific membrane antigen‐positron emission tomography/computed tomography (PSMA‐PET/CT) for primary staging were enrolled in the present, retrospective study.